Overview

IMCgp100-401 Rollover Study

Status:
Terminated

Trial end date:
2019-04-22

Target enrollment:

Participant gender:

Summary

IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).

Phase:

Phase 2

Details

Lead Sponsor:

Immunocore Ltd